CClinicalTrials.gg
SuspendedNCT07578285Updated Jul 14, 2026

A Study Of Starting Strength Barbell Training

An interventional study of Progressive Barbell Strength Training in Blood Pressure, Lipid Profile and Fasting Glucose, sponsored by Mayo Clinic. Suspended at 1 site in United States. Open to participants aged 15 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

Why this study was suspended
Funding
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
15 Years to 100 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effect of a 12-week coached Starting Strength barbell training program on systolic and diastolic blood pressure.

02

Conditions studied

  • Blood Pressure
  • Lipid Profile
  • Fasting Glucose
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adults aged 18-100 years
  • Sedentary or minimally active (less than 150 minutes of moderate-intensity physical activity per week)
  • No participation in structured resistance training programs within the past 6 months.
  • Able to safely participate in resistance training as determined by medical screening
  • Willing to commit to 3 training sessions per week for 12 weeks
  • Able to provide informed consent
  • Willing to obtain pre- and post-intervention laboratory tests from the same laboratory company.

Exclusion criteria

Exclusion Criteria:

  • Current participation in structured resistance training programs
  • Cardiovascular disease requiring activity restriction
  • Uncontrolled hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
  • Musculoskeletal conditions precluding safe barbell training
  • Changes in lipid-lowering or antihypertensive medications within 3 months prior to enrollment
  • Known cardiovascular, metabolic, or renal disease that would preclude safe participation in resistance training
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Starting Strength barbell training program

    12-week coached, progressive overload barbell strength training program (Starting Strength)

    Other: Progressive Barbell Strength Training

Interventions

  • OtherProgressive Barbell Strength Training

    Subjects will participate in a 12-week barbell training program, 3 days per week for approximately 60 minutes each session. Training sessions will be conducted by Starting Strength certified coaches at Starting Strength Scottsdale gym. Core barbell movements including but not limited to: squat, deadlift, bench press, overhead press, and power clean.

06

What researchers measure

Primary outcomes

  1. Change in systolic blood pressure

    Blood pressure will be measured using automated oscillometric device, and reported in millimeters of mercury (mmHg)

    Time frame: Baseline, 16 weeks

  2. Change in diastolic blood pressure

    Blood pressure will be measured using automated oscillometric device, and reported in millimeters of mercury (mmHg)

    Time frame: Baseline, 16 weeks

Secondary outcomes

  1. Change in total cholesterol

    Total cholesterol is the sum of a person's HDL cholesterol, LDL cholesterol, and 20% of their triglyceride levels. Healthy total cholesterol is less than 200 mg/dL of blood

    Time frame: Baseline, 16 weeks

  2. Change in low-density lipoprotein cholesterol (LDL-C)

    Low-density lipoprotein cholesterol (HDL-C) is measured via blood sample and reported in milligrams per deciliter (mg/DL). Results 100 mg/DL and below are considered healthier.

    Time frame: Baseline, 16 weeks

  3. Change in high-density lipoprotein cholesterol (HDL-C)

    High-density lipoprotein cholesterol (HDL-C) is measured via blood sample and reported in milligrams per deciliter (mg/DL). Results 60 mg/DL and above are considered healthier.

    Time frame: Baseline, 16 weeks

  4. Change in triglycerides

    Triglycerides are measured via blood sample and reported in milligrams per deciliter (mg/DL). Results 150 mg/DL and below are considered normal levels.

    Time frame: Baseline, 16 weeks

  5. Change in fasting glucose

    Blood sample taken after an overnight fast. Reported in millimoles per liter (mmol/l)

    Time frame: Baseline, 16 weeks

07

Study locations

1 site
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578285
Lead sponsor
Mayo Clinic
Responsible party
Joshua Lee (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
May 11, 2026
Start date
Jul 1, 2027 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Jul 14, 2026

Study contacts

Joshua Lee, PA-C,MPAS
principal investigator · Mayo Clinic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion